---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044345"
form_type: "8-K"
ticker: "LQDA"
cik: "0001819576"
company_name: "Liquidia Corp"
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:23:12.186234+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Liquidia wins dismissal of UTHR cross-claim over YUTREPIA PH-ILD label; FDA approval path cleared

## Summary
- District Court dismissed UTHR's cross-claim without prejudice for lack of standing and ripeness.
- FDA can grant final YUTREPIA approval after regulatory exclusivity expires on May 23, 2025.
- PDUFA goal date for YUTREPIA NDA remains May 24, 2025.
- UTHR retains the right to appeal the court's ruling.
- CEO cites court decision as validating FDA's acceptance of PH-ILD indication in NDA.

## SEC filing metadata
- accession: 0001104659-25-044345
- form_type: 8-K
- ticker: LQDA
- cik: 0001819576
- company_name: Liquidia Corp
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/0001104659-25-044345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819576/000110465925044345/tm2514002d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044345
- JSON: https://secwatch.observer/filing/0001104659-25-044345.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.